ангиотензин II. 的使用. 在人类中具有上腺性同情性约束作用
D Lyons1, J Webster, N Benjamin
1Clinical Age Research Unit, Kings College Hospital, Denmark Hill, London, UK.
Circulation
|March 1, 1995
概括
ангиотензин II (Ang II) 在人类中引起血管收缩,部分是通过交感神经系统的激活. 与托胺相比,用托胺阻断α受体减少了Ang II对前臂血流的影响.
科学领域:
- 心血管生理学心血管生理学
- 神经内分泌学神经内分泌学
背景情况:
- ангиотензин II (Ang II) 在上腺神经传递中起作用.
- ангиотензин转化酶抑制剂可能会影响甲基荷兰胺水平.
- Ang II 的血管收缩作用需要在人类中进一步研究.
研究的目的:
- 调查同情调解在Ang II诱导的血管收缩中的作用.
- 为了比较Ang II在α受体阻塞和血管扩张期间对前臂血流的影响.
主要方法:
- 在健康志愿者手臂动脉中进行Ang II的局部动脉内输液.
- 用芬托胺对 postsynaptic 阿尔法受体进行药理阻塞.
- 与在尼普鲁塞德诱导的血管扩张期间的Ang II输液进行比较.
- 测量前臂血液流动,使用张力计囊造影.
主要成果:
- 在托胺阻塞 (28.1%) 期间,与托胺血管扩张 (52.9%) 相比,Ang II诱导的前臂血流减少显着较低.
- Ang II对血液流动的剂量反应曲线的斜率在托胺阻塞期间明显不那么 (-0.098),而不是在托胺施用期间 (-0.16).
结论:
- 外源性Ang II对人类前臂阻力血管的血管收缩作用的很大一部分是由交感通路介导的.
相关概念视频
Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...


